| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H8NO4.Na |
| Molecular Weight | 241.1753 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC1=CC2=C(C=C1C)C(=O)C(C2=O)=[N+]([O-])[O-]
InChI
InChIKey=KGLVEXSGYXXSOJ-UHFFFAOYSA-N
InChI=1S/C11H8NO4.Na/c1-5-3-7-8(4-6(5)2)11(14)9(10(7)13)12(15)16;/h3-4H,1-2H3;/q-1;+1
| Molecular Formula | C11H8NO4 |
| Molecular Weight | 218.1855 |
| Charge | -1 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sodium nivimedone (BRL10833) is an orally administered anti-allergic agent with similar properties to DSCG. Nivimedone inhibited IgE-mediated passive cutaneous anaphylactic (PCA) reactions in the rat and the antigen-induced release of histamine from human lung passively sensitized with atopic serum. The pharmacological potency of sodium nivimedone when compared to DSCG was 42 times greater in the human lung system and approximately ten times greater in rat PCA. In addition, single doses of sodium nivimedone given by mouth inhibited antigen-induced bronchoconstriction in man.
Approval Year
PubMed
Sample Use Guides
Sodium nivimedone (BRL10833) given at an oral dose of 200 mg thrice daily, was compared, after a preliminary standardization week, with placebo in a 6-week double-blind cross-over trial.
Route of Administration:
Oral
